Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening Regimen Comparing Two Months Moxifloxacin, Isoniazid, Rifampicin, Pyrazinamide Followed by Two Months Moxifloxacin, Isoniazid, Rifampicin Versus the Standard Regimen (Two Months Ethambutol, Isoniazid, Rifampicin, Pyrazinamide Followed by Four Months Isoniazid and Rifampicin) for the Treatment of Adults With Pulmonary Tuberculosis.

Next Previous
Trial Profile

A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening Regimen Comparing Two Months Moxifloxacin, Isoniazid, Rifampicin, Pyrazinamide Followed by Two Months Moxifloxacin, Isoniazid, Rifampicin Versus the Standard Regimen (Two Months Ethambutol, Isoniazid, Rifampicin, Pyrazinamide Followed by Four Months Isoniazid and Rifampicin) for the Treatment of Adults With Pulmonary Tuberculosis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Moxifloxacin (Primary) ; Ethambutol; Isoniazid; Pyrazinamide; Rifampicin
  • Indications Pulmonary tuberculosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms REMoxTB

Most Recent Events

  • 22 Feb 2023 Results(n=711) of pooled analysis from four Phase 3 clinical trials (OFLOTUB NCT00216385, REMoxTB NCT00864383, RIFAQUIN ISRCTN44153044, S31/A5349 NCT02410772) assessing Tb Outcomes in People Living with Hiv presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
  • 17 Mar 2021 Results (n= 2744) of pooled analysis from 3 studies (NCT00864383, NCT01498419 & NCT00694629) evaluating short term time to positivity (TTP) biomarker in liquid culture as a predictor of individual TSCC and trial level HR, presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
  • 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top